2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Peptide-Drug Conjugates (PDCs)

Peptide-Drug Conjugates (PDCs)

ADC-Related Custom Services

Peptide-Drug Conjugates (PDCs)

Peptide-drug conjugates (PDCs) are the next generation of targeted therapeutics drug after antibody-drug conjugate (ADCs) and hold broad prospects in fields such as tumor treatment. PDCs combine peptides selectivity with chemotherapeutic drugs lethality, with the core benefits of enhanced cellular permeability and improved drug selectivity. PDCs consist of three important components: peptides, linkers and cytotoxic payloads. Among them, peptides mainly include homing peptides and cell-penetrating peptides, which can affect the efficiency of drug endocytosis. The ideal peptide should have high affinity, stability, and so on. Cytotoxins is the key to killing tumor cells and has both therapeutic and imaging functions. Cytotoxins for coupling have four requirements as followed: a clear mechanism of action, a small molecular weight, high cytotoxicity and retained anti-tumor activity after chemical coupling to the peptide. The linker needs to connect the peptide and the cytotoxic payload and can be divided into cleavable and non-cleavable types. The choice of linker is crucial and requires consideration of the microenvironment in which the PDC is located to avoid interfering with the binding affinity of the peptide to its receptor and the drug efficacy. The linker must have a certain level of stability to prevent premature and nonspecific drug release[1].

Peptide-Drug Conjugates (PDCs) Related Products (29):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P4073
    ANG1005
    		98.83%
    ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system.
    ANG1005
  • HY-160719
    2-octynoic acid-BSA
    NHS-activated 2-octynoic acid-BSA is an immunogen used to establish a mouse model of primary biliary cholangitis (PBC). When used in combination with Complete Freund's Adjuvant (HY-153808), NHS-activated 2-octynoic acid-BSA stimulates the body's immune system, which recognizes it as a foreign antigen and triggers an immune response against autologous biliary epithelial cells. This leads to the production of anti-PDC-E2 antibodies, causing bile duct damage and inflammation. NHS-activated 2-octynoic acid-BSA is promising for use in primary biliary cholangitis research.
    2-octynoic acid-BSA
  • HY-N13356
    L-gamma-Glutamyl-L-threonine
    		99.97%
    L-gamma-Glutamyl-L-threonine (gamma-Glutamylthreonine; H-γ-Glu-Thr-OH; γ-Glu-Thr) is a dipeptide obtained through the formal condensation of the L-glutamic acid side chain carboxyl group and the L-threonine amino group. L-gamma-Glutamyl-L-threonine is present in high concentrations in human urine and exhibits antibacterial activity against Gram-negative bacterial. L-gamma-Glutamyl-L-threonine is also a flavor compound. Gamma-Glutamylthreonine is a metabolite catalyzed by γ-glutamyl transpeptidase and is associated with immune regulation. Gamma-Glutamylthreonine can be used in research on inflammation and bacterial infections.
    L-gamma-Glutamyl-L-threonine
  • HY-P10741
    DOTA-EB-TATE
    DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-EB-TATE
  • HY-P10762
    Ricorfotide vedotin
    		98.45%
    Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma).
    Ricorfotide vedotin
  • HY-183866
    MPD-1
    MPD-1 (Maleimide-KGDEVD-doxorubicin) is a peptide drug conjugate (PDC). MPD-1 releases Doxorubicin (HY-15142) via radiation-activated caspase-3 cleavage, triggering a cytotoxic amplification cascade at the tumor site. MPD-1 enhances CD8+ T cell tumor infiltration, and activates antigen-presenting cells. MPD-1 enables dual-trigger payload release, amplifies cytotoxicity via in situ feedback, and selectively delivers payload to tumor microenvironments via enhanced albumin metabolism and macropinocytosis. MPD-1 exhibits antitumor efficacy in mouse colorectal cancer models. MPD-1 can be used for the research of colorectal cancer.
    MPD-1
  • HY-16532
    Zoptarelin doxorubicin
    Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro.
    Zoptarelin doxorubicin
  • HY-P10772A
    L2P4 TFA
    		98.25%
    L2P4 TFA is a peptide-based and EBNA1 targeting fluorescent probe, which inhibits the EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. L2P4 TFA exhibits cytotoxicity in EBV-positive C666-1 cell with LC50 of 46.4 μM.
    L2P4 TFA
  • HY-P4118
    EB1 peptide
    		99.02%
    EB1 peptide (Penetrating analog) is an endosomolytic agent and siRNA delivery agent. EB1 peptide forms an amphipathic alpha helix upon protonation in early-late endosomes, drives endosomal membrane permeabilization, and enables endocytosed siRNA escape into the cytosol. EB1 peptide facilitates biologically active siRNA cellular uptake and targeted gene silencing. EB1 peptide forms complexes with siRNA. EB1 peptide can be used for drug delivery research.
    EB1 peptide
  • HY-P10740
    CBP-1018
    		99.21%
    CBP-1018 is a PDC (peptide-drug conjugate) formed by conjugating Monomethyl auristatin E (HY-15162) to a dual-targeting ligand of FLOR1/PSMA (prostate-specific membrane antigen) via a linker (HY-78738). CBP-1018 binds to FLOR1 and prostate-specific membrane antigen (PSMA). CBP-1018 is applicable to the research of solid tumors and metastatic castration-resistant prostate cancer.
    CBP-1018
  • HY-106195
    L 377202
    L 377202 is a peptide-drug conjugate (PDC). L 377202 consists of Doxorubicin (HY-15142A) and a prostate-specific antigen (PSA)-hydrolyzable peptide. L 377202 demonstrates strong inhibitory effects on PSA-secreting prostate cancer cells. L 377202 is promising for research of prostate cancer.
    L 377202
  • HY-P10773
    CTP-amiodarone
    CTP-amiodarone is a cell-penetrating conjugate of cardiomyocyte targeting peptide and Amiodarone (HY-14187). CTP-amiodarone exhibits antiarrhythmic efficacy through block of Na+, K+, Ca2+ channels and β-adrenergic receptors.
    CTP-amiodarone
  • HY-P10760
    PhAc-ALGP-Dox
    PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells.
    PhAc-ALGP-Dox
  • HY-P2619
    BPP 5a
    BPP 5a is a bradykinin-potentiating peptide with vasorelaxant activity, which is found in Bothrops jararaca venom. BPP 5a is an angiotensin-converting enzyme (ACE) inhibitor with a Ki value of 400 nM. BPP 5a is promising for research of hypertension and cardiovascular diseases.
    BPP 5a
  • HY-P10870
    Pep1-DNP conjugate 9
    Pep1-DNP conjugate 9 is a functionalized peptide which is composed of the DNP-Hapten and the FGFR1 binding peptide. Pep1-DNP conjugate 9 exhibits good affinity to FGFR1 with KD of 5.01 μM. Pep1-DNP conjugate 9 recruits anti-DNP antibodies to the surface of FGFR1-positive cells, inhibits the FGF2-induced proliferation in rat skeletal myoblast cells, and induces apoptosis. Pep1-DNP conjugate 9 exhibits antitumor efficacy in mouse models.
    Pep1-DNP conjugate 9
  • HY-106154
    DTS-201
    DTS-201 (CPI-0004) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer.
    DTS-201
  • HY-P10775
    BT1769
    BT1769 is a MT1-MMP-targeted (KD = 3.35 nM) Bicycle toxin conjugate. BT1769 can be used in the study for osteosarcoma. BT1769 consists of a novel bicyclic targeting peptide that selectively binds MT1-MMP; a cytotoxin MMAE; and an enzymatically cleavable dipeptide linker.
    BT1769
  • HY-P11204
    DDDEEKC
    DDDEEKC is a bioinspired peptide sequence that can selectively adsorb onto the enamel surface (mimicking the role of salivary acquired pellicle protein statherin), acting as a "target - guiding agent" for tooth enamel remineralization. DDDEEKC enhances the regeneration of hydroxyapatite (HAP). DDDEEKC is promising for research of in-situ remineralization repair of enamel demineralization damage (such as dental caries).
    DDDEEKC
  • HY-P10765
    DTS-108
    DTS-108 is a prodrug of SN38 (HY-13704) (a Topoisomerase I inhibitor). DTS-108 is a conjugate generated by linking SN38 to a human oligopeptide via an esterase sensitive cross-linker. DTS-108 exhibits anti-tumor activity against colorectal, lung, and mammary cancer.
    DTS-108
  • HY-P10782
    Pt(IV)-M13
    Pt(IV)-M13 is a BBB-penetrable Platinum (IV) prodrug-perfluoroaryl macrocyclic peptide conjugate. Pt(IV)-M13 is cytotoxic to glioma stem cells and increases uptake of platinum in the brain. Pt(IV)-M13 can be used in the study of glioblastoma.
    Pt(IV)-M13